Fulminant Ocular Toxoplasmosis: The Hazards of Corticosteroid Monotherapy

REFERENCES

• Vasconcelos-Santos DV. Ocular manifestations of systemic disease: toxoplasmosis. Curr Opin Ophthalmol. 2012;23(6):543–550.
   PubMed Web of Science ®Google Scholar
• Orefice F, Vasconcelos-Santos DV, Cordeiro CA, et al. Toxoplasmosis. In: Foster CS, Vitale AT, eds. Diagnosis and Treatment of Uveitis. 2nd ed. New Delhi, India: Jaypee-Highlights Medical Publishers; 2013:543–568.
   Google Scholar
• Rothova A. Ocular manifestations of toxoplasmosis. Curr Opin Ophthalmol. 2003;14(6):384–388.
   PubMedGoogle Scholar
• Maenz M, Schlüter D, Liesenfeld O, et al. Ocular toxoplasmosis past, present, and new aspects of an old disease. Prog Retin Eye Res. 2014;39:77–106.
   PubMed Web of Science ®Google Scholar
• Holland GN. LX Edward Jackson memorial lecture. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol. 2003;136(6):973–988.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Corum I, Otuk B, et al. Active ocular toxoplasmosis in Turkish patients: a report on 109 cases. Int Ophthalmol. 2005;26(6):221–228.
   PubMedGoogle Scholar
• Talabani H, Mergey T, Year H, et al. Factors of occurrence of ocular toxoplasmosis. A review. Parasite. 2010;17(3):177–182.
   PubMed Web of Science ®Google Scholar
• Kijlstra A, Petersen E. Epidemiology, pathophysiology, and the future of ocular toxoplasmosis. Ocul Immunol Inflamm. 2014;22(2):138–147.
   PubMed Web of Science ®Google Scholar
• Kazokoglu H, Onal S, Tugal-Tutkun I, et al. Demographics and clinical features of uveitis in tertiary centers in Turkey. Ophthalmic Epidemiol. 2008;15(5):285–293.
   PubMed Web of Science ®Google Scholar
• Moshfeghi DM, Dodds EM, Couto CA, et al. Diagnostic approaches to severe, atypical toxoplasmosis mimicking acute retinal necrosis. Ophthalmology. 2004;111(4):716–725.
   PubMed Web of Science ®Google Scholar
• Elkins BS, Holland GN, Opremcak EM, et al. Ocular toxoplasmosis misdiagnosed as cytomegalovirus retinopathy in immunocompromised patients. Ophthalmology. 1994;101(3):499–507.
   PubMed Web of Science ®Google Scholar
• Fardeau C, Romand S, Rao NA, et al. Diagnosis of toxoplasmic retinochoroiditis with atypical features. Am J Ophthalmol. 2002;134(2):196–203.
   PubMed Web of Science ®Google Scholar
• Smith JR, Cunningham ET. Atypical presentations of ocular toxoplasmosis. Curr Opin Ophthalmol. 2002;13(6):387–92.
   PubMedGoogle Scholar
• Hazan A, Patel RM, Levinson D, et al. A typical bilateral Toxoplasma retinochoroiditis in a bone marrow transplant patient with negative serum titers. J Ophthalmic Inflamm Infect. 2013;3(1):23–27.
   PubMedGoogle Scholar
• Singer MA, Hagler WS, Grossniklaus HE. Toxoplasma gondii retinochoroiditis after liver transplantation. Retina. 1993;13(1):40–45.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–16.
   PubMed Web of Science ®Google Scholar
• O’Connor GR, Frenkel JK. Dangers of steroid treatment in toxoplasmosis. Periocular injections and systemic therapy. Arch Ophthalmol. 1976;94(2):213.
   PubMed Web of Science ®Google Scholar
• Rush R, Sheth S. Fulminant toxoplasmic retinochoroiditis following intravitreal triamcinolone administration. Indian J Ophthalmol. 2012;60(2):141–143.
   PubMed Web of Science ®Google Scholar
• Backhause O, Bhan KJ, Bishop F. Intravitreal triamcinolone acetonide as an adjunct in the treatment of severe ocular toxoplasmosis. Eye (Lond). 2008;22(9):1200–1201.
   PubMed Web of Science ®Google Scholar
• Nóbrega MJ, Rosa EL. Toxoplasmosis retinochoroiditis after photodynamic therapy and intravitreal triamcinolone for a supposed choroidal neovascularization: A case report. Arq Bras Oftalmol. 2007;70(1):157–60.
   PubMedGoogle Scholar
• Papadia M, Aldigeri R, Herbort CP. The role of serology in active ocular toxoplasmosis. Int Ophthalmol. 2011;31(6):461–465.
   PubMedGoogle Scholar
• Talabani H, Asseraf M, Yera H, et al. Contributions of immunoblotting, real-time PCR, and the Goldmann-Witmer coefficient to diagnosis of atypical toxoplasmic retinochoroiditis. J Clin Microbiol. 2009;47(7):2131–2135.
   PubMed Web of Science ®Google Scholar
• Ongkosuwito JV, Bosch-Driessen EH, Kijlstra A, et al. Serologic evaluations of patients with primary and recurrent ocular toxoplasmosis for evidence of recent infection. Am J Ophthalmol. 1999;128(4):407–412.
   PubMed Web of Science ®Google Scholar
• Westeneng AC, Rothova A, de Boer JH, et al. Infectious uveitis in immunocompromised patients and the diagnostic value of polymerase chain reaction and Goldmann-Witmer coefficient in aqueous analysis. Am J Ophthalmol. 2007;144(5):781–785.
   PubMed Web of Science ®Google Scholar
• de Boer JH, Verhagen C, Bruinenberg M, et al. Serologic and polymerase chain reaction analysis of intraocular fluids in the diagnosis of infectious uveitis. Am J Ophthalmol. 1996;121(6):650–658.
   PubMed Web of Science ®Google Scholar
• Harper TW, Miller D, Schiffman JC, et al. Polymerase chain reaction analysis of aqueous and vitreous specimens in the diagnosis of posterior segment infectious uveitis. Am J Ophthalmol. 2009;147(1):140–147 e2.
   PubMed Web of Science ®Google Scholar
• Errera MH, Goldschmidt P, Batellier L, et al. Real-time polymerase chain reaction and intraocular antibody production for the diagnosis of viral versus toxoplasmic infectious posterior uveitis. Graefes Arch Clin Exp Ophthalmol. 2011;249(12):1837–1846.
   PubMed Web of Science ®Google Scholar
• Bourdin C, Busse A, Kouamou E, et al. PCR detection of Toxoplasma gondii DNA in blood and ocular samples for the diagnosis of ocular toxoplasmosis. J Clin Microbiol. 2014;52(11):3987–3991.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Scott UI, Brown GC, et al. Interventions for toxoplasma retinochoroiditis: A report by the American Academy of Ophthalmology. Ophthalmology. 2013;120(2):371–378.
   PubMed Web of Science ®Google Scholar
• de-la-Torre A, Stanford M, Curi A, et al. Therapy for ocular toxoplasmosis. Ocul Immunol Inflamm. 2011;19(5):31–320.
   Web of Science ®Google Scholar
• Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 2002;134(1):102–114.
   PubMed Web of Science ®Google Scholar
• Engstrom RE Jr, Holland GN, Nussenblatt RB, et al. Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 1991;111(5):601–610.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118(1):134–141.
   PubMed Web of Science ®Google Scholar
• Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MSA, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol. 2002;134(1):34–40.
   PubMed Web of Science ®Google Scholar
• Baharivand N, Mahdavifard A, Fouladi RF. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial. Int Ophthalmol. 2013;33(1):39–46.
   PubMed Web of Science ®Google Scholar
• Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology. 2005;112(11):1876–1882.
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Touitou V, Fardeau C, et al. Toxoplasmosis: new challenges for an old disease. Eye (Lond). 2012;26(2):241–244.
   PubMed Web of Science ®Google Scholar
• Yazici A, Ozdal PC, Taskintuna I, et al. Trimethoprim/Sulfamethoxazole and azithromycin combination therapy for ocular toxoplasmosis. Ocul Immunol Inflamm. 2009;17(4):289–291.
   PubMed Web of Science ®Google Scholar
• Lasave AF, Diaz-Llopis M, Muccioli C, et al. Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months. Ophthalmology. 2010;117(9):1831–1838.
   PubMed Web of Science ®Google Scholar
• Martinez CE, Zhang D, Conway MD, et al. Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine. Int Ophthalmol. 1998;22(2):85–88.
   PubMed Web of Science ®Google Scholar
• Felix JPF, Lira RPC, Zacchia RS, et al. Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of toxoplasma gondii retinochoroiditis: randomized controlled clinical trial. Am J Ophthalmol. 2014:157(4):762–766.
   PubMed Web of Science ®Google Scholar
• Silveira C, Muccioli C, Nussenblatt R, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis: 10 years of follow-up. Ocul Immunol Inflamm. 2015;23(3):246–247.
   PubMed Web of Science ®Google Scholar
• Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Ophthalmol. 2004;137(1):1–17.
   PubMed Web of Science ®Google Scholar
• Adan A, Giralt J, Alvarez G, et al. Pars plana vitrectomy for vitreoretinal complications of ocular toxoplasmosis. European J Ophthalmol. 2009;19(6):1039–1043.
   PubMed Web of Science ®Google Scholar